India biopharma revenues rise to $2.5 bn

Updated on 7 August 2012

biopharmaaMoreover, the vaccines sector in India, which is a major supplier of vaccines to UNICEF, within the biopharma space witnessed a continued growth in 2011-12, with companies like Haffkine Biopharmaceutical and Serum Institute recording high growth of 100 percent and 60 percent respectively. Also, the animal vaccine market, which is about $60-to-70 million, registered a 15 percent .

Furthermore, the diagnostics market in India also witnessed 20 percent growth, which is the faster than any country in the world (the growth in the US being only one-to-two). Lets hope that by looking at the scope of growth in the various domains of the biopharma sector, the government takes further steps to provide encouragement to this sector.

Previous 1 2 Next

Leave a Reply

Post Comment

Special Features

Survey Box

Chinese Bird Flu H5N7

Have Chinese scientists done the right thing by fusing human and avian flu strains to create new killer viruses?

Send this article by email

X